There's a new biomarker in the mix that could help diagnose patients at high risk for tuberculosis and lead to targeted treatments to combat it.
Here's why: The top 5 diagnostics-related venture capital deals in the 2014 second quarter are much more robust than those from the previous quarter, reflecting a larger med tech trend that produced a healthy hike in both deal value and volume versus Q1.
We all know the life sciences industry produces plenty of hype about new diagnostic advances, cutting-edge treatments and lifesaving surgeries. Many are profoundly amazing and life-changing inventions that have saved countless lives. But the truth is that much of patient diagnosis and care remains guesswork, trial, error and hope. Read more >>
POPULAR COMMENT THREADS
Illumina has inked deals with three major Big Pharma companies with a goal of developing a universal gene-sequencing companion diagnostic test system focused on cancer.
Researchers have identified a new biomarker for rheumatoid arthritis that could help with earlier diagnosis and treatment.
Corgenix, in the news recently for its Ebola virus test, will sell itself to a competitor based in Germany for about $16 million. The news comes 5 months after the Denver company revealed it might seek to become an M&A target, in part, to reduce costs and boost efficiency and market reach.
Roche's Ventana Medical Systems is building a new distribution center in Arizona and plans to generate additional jobs in the process.
The FDA has signed off on a new, highly specific biomarker blood test designed by an Idaho company to quickly spot Type 1 diabetes.
Tissue-based companion diagnostics company Flagship Biosciences said it will join with Sarepta Therapeutics to automate and quicken measurement of a key biomarker for muscular dystrophy.
From Our Sister Sites
Among all the pharma companies, Novo Nordisk always stood out for its relentless R&D focus on diabetes and obesity. Today, the Danish company amped up that concentration another notch, jettisoning a group of clinical programs and winding down its work in anti-inflammatory treatments. And the pharma player added that the move would hit some 400 staffers, with close to half likely to lose their jobs at Novo.
German CRO Cenix BioScience has signed a deal with a BASF subsidiary to help ferret out new biomarkers, focusing on the growing field of metabolomics.